1.
Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
by GEERTS, William H
Chest, 2004, Vol.126 (3), p.338S-400S
2.
Protein detection using proximity-dependent DNA ligation assays
by Fredriksson, Simon
Nature biotechnology, 2002-05, Vol.20 (5), p.473-477
3.
Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma
by Subbarao, Padmaja
Journal of Allergy and Clinical Immunology, 2006, Vol.117 (5), p.1008-1013
4.
Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt
by STØRLING, J
Diabetologia, 2005, Vol.48 (10), p.2039-2050
5.
Chronic Intracerebroventricular Infusion of Nociceptin/Orphanin FQ Produces Body Weight Gain by Affecting Both Feeding and Energy Metabolism in Mice
by Matsushita, Hiroko
Endocrinology (Philadelphia), 2009-06, Vol.150 (6), p.2668-2673
6.
Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide
by Ruszniewski, Philippe
Neuroendocrinology, 2005-01, Vol.80 (4), p.244-251
7.
Allopregnanolone concentration and mood- : a bimodal association in postmenopausal women treated with oral progesterone
by ANDREEN, Lotta
Psychopharmacologia, 2006, Vol.187 (2), p.209-221
8.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
by Robert, Caroline, Prof
The Lancet (British edition), 2014, Vol.384 (9948), p.1109-1117
9.
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-b...
by FitzGerald, J Mark, Dr
The Lancet (British edition), 2016, Vol.388 (10056), p.2128-2141
10.
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
by Golden, Encouse B, MD
The lancet oncology, 2015, Vol.16 (7), p.795-803
11.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
by El-Khoueiry, Anthony B, Dr
The Lancet (British edition), 2017, Vol.389 (10088), p.2492-2502
12.
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2 -agonists (SIROCCO): a randomised, mul...
by Bleecker, Eugene R
The Lancet (British edition), 2016-10-29, Vol.388 (10056), p.2115
13.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
by Wu, Yi-Long
The lancet oncology, 2017-11, Vol.18 (11), p.1454-1466
14.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 s...
by Balar, Arjun V
The lancet oncology, 2017-11, Vol.18 (11), p.1483-1492
15.
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
by Vandenberg, Laura N
Endocrine reviews, 2012-06, Vol.33 (3), p.378-455
16.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
by Shaw, Alice T
The lancet oncology, 2017-12, Vol.18 (12), p.1590-1599
17.
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
by Reich, Kristian, Prof
The Lancet (British edition), 2017, Vol.390 (10091), p.276-288
18.
The Endocannabinoid System and the Brain
by MECHOULAM, Raphael
Annual review of psychology, 2013, Vol.64 (1), p.21-47
19.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
by Heinemann, Volker, Prof
The lancet oncology, 2014, Vol.15 (10), p.1065-1075
20.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-bl...
by Wilke, Hansjochen, Prof
The lancet oncology, 2014, Vol.15 (11), p.1224-1235
